Reneo Pharmaceuticals (NASDAQ:RPHM) Stock Rating Reaffirmed by HC Wainwright

Reneo Pharmaceuticals (NASDAQ:RPHMGet Free Report)‘s stock had its “neutral” rating reissued by stock analysts at HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They presently have a $1.50 target price on the stock. HC Wainwright’s price target suggests a potential downside of 5.66% from the stock’s previous close.

Reneo Pharmaceuticals Stock Down 12.2 %

RPHM opened at $1.59 on Tuesday. The company has a market cap of $53.14 million, a price-to-earnings ratio of -0.73 and a beta of 0.22. The firm’s fifty day simple moving average is $1.69 and its two-hundred day simple moving average is $2.90. Reneo Pharmaceuticals has a 52-week low of $0.98 and a 52-week high of $9.45.

Reneo Pharmaceuticals (NASDAQ:RPHMGet Free Report) last issued its quarterly earnings results on Thursday, March 28th. The company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.15). On average, research analysts forecast that Reneo Pharmaceuticals will post -0.83 EPS for the current year.

Institutional Investors Weigh In On Reneo Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Dorsey Wright & Associates acquired a new position in Reneo Pharmaceuticals during the third quarter worth about $28,000. SG Americas Securities LLC acquired a new stake in shares of Reneo Pharmaceuticals in the fourth quarter valued at approximately $35,000. Jump Financial LLC purchased a new position in Reneo Pharmaceuticals during the fourth quarter worth approximately $41,000. Pale Fire Capital SE boosted its stake in Reneo Pharmaceuticals by 102.7% during the fourth quarter. Pale Fire Capital SE now owns 30,100 shares of the company’s stock worth $48,000 after buying an additional 15,249 shares during the last quarter. Finally, Marquette Asset Management LLC acquired a new stake in shares of Reneo Pharmaceuticals in the 1st quarter worth $122,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

About Reneo Pharmaceuticals

(Get Free Report)

Reneo Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders.

Featured Articles

Analyst Recommendations for Reneo Pharmaceuticals (NASDAQ:RPHM)

Receive News & Ratings for Reneo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reneo Pharmaceuticals and related companies with's FREE daily email newsletter.